Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: Consequences of low adherence

Arthritis and Rheumatism

Volumn 65, Issue 6, 2013, Pages 1421-1429

  Waimann, Christian A ^a   Marengo, Maria F ^a   De Achaval, Sofia ^a   Cox, Vanessa L ^a   Garcia Gonzalez, Araceli ^a   Reveille, John D ^a   Richardson, Marsha N ^a   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG MONITORING; ELECTRONIC MONITORING; ETHNIC GROUP; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MONITOR; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SOCIAL STATUS; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CULTURAL DIVERSITY; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PREDNISONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84878524281     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37917     Document Type: Article

References (29)

1. Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA,. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 291-8.
2. Shi L, Hudges M, Yurgin N, Boye KS,. Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). Expert Rev Pharmacoecon Outcomes Res 2007; 7: 187-202. (Pubitemid 46690969)
3. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 821-4. (Pubitemid 46846706)
4. Vermeire E, Hearnshaw H, Van Royen P, Denekens J,. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331-42. (Pubitemid 32989555)
5. Borah BJ, Huang X, Zarotsky V, Globe D,. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009; 25: 1365-77.
6. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R,. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008; 59: 1519-26.
7. De Klerk E, van der Heijde D, van der Tempel H, van der Linden S,. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 1999; 26: 2635-41.
8. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45: S66-76.
9. Harley CR, Frytak JR, Tandon N,. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9 Suppl 6: S136-S143. (Pubitemid 37345201)
10. Ward MM, Lotstein DS, Bush TM, Lambert RE, van Vollenhoven R, Neuwelt CM,. Psychosocial correlates of morbidity in women with systemic lupus erythematosus. J Rheumatol 1999; 26: 2153-8. (Pubitemid 29487009)
11. De Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S, de Klerk E, et al. The Compliance-Questionnaire-Rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003; 30: 2469-75. (Pubitemid 37413910)
12. Feinstein AR,. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377-8. (Pubitemid 20215672)
13. Urquhart J,. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-56. (Pubitemid 27199228)
14. De Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout [published erratum appears in J Rheumatol 2003;30:423]. J Rheumatol 2003; 30: 44-54. (Pubitemid 36077771)
15. Dunbar-Jacob J, Holmes JL, Sereika S, Kwoh CK, Burke LE, Starz TW, et al. Factors associated with attrition of African Americans during the recruitment phase of a clinical trial examining adherence among individuals with rheumatoid arthritis. Arthritis Rheum 2004; 51: 422-8. (Pubitemid 38725142)
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
17. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP,. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-53. (Pubitemid 14231480)
18. Ware JE Jr, Sherbourne CD,. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
19. Sherbourne CD, Stewart AL,. The MOS social support survey. Soc Sci Med 1991; 32: 705-14.
20. Andresen EM, Malmgren JA, Carter WB, Patrick DL,. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994; 10: 77-84. (Pubitemid 24144960)
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
22. Van der Heijde D,. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5. (Pubitemid 29125603)
23. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7. (Pubitemid 351160875)
24. De Achaval S, Suarez-Almazor ME,. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol 2010; 5: 313-26.
25. Marengo M, Waimann C, Achaval S, Zhang H, Garcia-Gonzalez A, Richardson M, et al. Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012; 21: 1158-65.
26. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A, Tuncay R, et al. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 2007; 27: 743-6. (Pubitemid 46716729)
27. Van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W,. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009; 36: 2164-70.
28. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119: 2051-7.
29. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-41.